Search research articles
Contact Us
Filters
Showing results (101-110 of 126) with videos related to
Page
of 13
Sort By:
Blood
|
October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W Flinn, Peter Hillmen, Marco Montillo, et al.
Intensive Care Medicine
|
September 4, 2024
Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial
Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, et al.
Blood
|
October 29, 2005
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
Sylvain Choquet, Veronique Leblond, Raoul Herbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
Cyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Communications Medicine
|
March 6, 2026
Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
Annelien Morlion, Philippe Decruyenaere, Kathleen Schoofs, et al.
Hemasphere
|
January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
Roch Houot, Viola Poeschel, Bettina Altmann, et al.
Plos One
|
December 8, 2025
Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment: Process evaluation study of the CODE intervention in doctors and nurses working in ten acute hospital wards
Ruth Piers, Let Dillen, Katrijn Goethals, et al.
Lancet (London, England)
|
December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles, John Francis Seymour, Fritz Offner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
Bertrand Coiffier, Weimin Li, Erin D Henitz, et al.
The Lancet. Oncology
|
February 25, 2018
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
Sarah Huet, Bruno Tesson, Jean-Philippe Jais, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 126) with videos related to
Sort By:
Page
of 13
Blood
|
October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W Flinn, Peter Hillmen, Marco Montillo, et al.
Intensive Care Medicine
|
September 4, 2024
Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial
Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, et al.
Blood
|
October 29, 2005
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
Sylvain Choquet, Veronique Leblond, Raoul Herbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
Cyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Communications Medicine
|
March 6, 2026
Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
Annelien Morlion, Philippe Decruyenaere, Kathleen Schoofs, et al.
Hemasphere
|
January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
Roch Houot, Viola Poeschel, Bettina Altmann, et al.
Plos One
|
December 8, 2025
Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment: Process evaluation study of the CODE intervention in doctors and nurses working in ten acute hospital wards
Ruth Piers, Let Dillen, Katrijn Goethals, et al.
Lancet (London, England)
|
December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles, John Francis Seymour, Fritz Offner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
Bertrand Coiffier, Weimin Li, Erin D Henitz, et al.
The Lancet. Oncology
|
February 25, 2018
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
Sarah Huet, Bruno Tesson, Jean-Philippe Jais, et al.
Page
of 13